B. Riley Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $670
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst William Woods maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $560 to $670.
B. Riley Securities analyst William Woods maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $560 to $670.